EMD Serono Inc., Merck KGaA’s North American drug development business, has officially taken up residence in Boston’s Seaport ...

Shares of Bicara Therapeutics—a biopharmaceutical company backed by Indian billionaire Kiran Mazumdar-Shaw—surged about 42% ...

Progression-free survival (PFS) in intermediate-stage hepatocellular carcinoma (HCC) improved by almost 5 months when a ...

Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...

After hours: September 18 at 7:59 PM EDT Loading Chart for MRK ...

Intermediate-stage hepatocellular carcinoma remains a challenge to treat. The new findings may lead to a new treatment ...

Recent research highlights the potential of microRNAs as cost-effective and less invasive biomarkers for early diagnosis and ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech that spans ...

Encore Boston Harbor brings Las Vegas vibes to the East Coast. With its timeless appeal and rich past, Boston attracts history buffs by the duck boat loads. However, Massachusetts’ capital ...